Antibe Therapeutics Inc (ATE.TO)

3.47 -0.11  -3.07% TSX Jul 27, 20:00 CAD
View Full Chart
Price Chart
View All ATE.TO News

News

View All Events

Events

Date Type Description
12/01/2020 Splits 1 to 10 Split
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • Description: Antibe Therapeutics Inc develops and out-licenses new pharmaceuticals. Its main objective is to develop its lead compound otenaproxesul, by satisfying the requirements of the relevant drug regulatory authorities while also satisfying the commercial licensing objectives of prospective global partners. It operates in two segments: Antibe and Citagenix. All of its revenue is generated from the Citagenix segment, which is a marketer and distributor of regenerative medicines serving the dental and orthopedic market places. Citagenix consists of branded biologics and medical devices that promote bone regeneration. The company's geographical segments are Canada, the United States, Europe, and the Rest of the World.
  • URL: https://www.antibethera.com
  • Investor Relations URL: N/A
  • HQ State/Province: Ontario
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Small Cap/Growth
  • Next Earnings Release: N/A
  • Last Earnings Release: N/A
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.